3//SEC Filing
Sofinnova Venture Partners X, L.P. 3
Accession 0000899243-20-020306
CIK 0001693011other
Filed
Jul 22, 8:00 PM ET
Accepted
Jul 23, 9:31 PM ET
Size
14.6 KB
Accession
0000899243-20-020306
Insider Transaction Report
Form 3
Sofinnova Venture Partners X, L.P.
10% Owner
Holdings
Series A-2 Convertible Preferred Stock
→ Common Stock (1,590,808 underlying)
HEALY JAMES
10% Owner
Holdings
Series A-2 Convertible Preferred Stock
→ Common Stock (1,590,808 underlying)
POWELL MICHAEL
10% Owner
Holdings
Series A-2 Convertible Preferred Stock
→ Common Stock (1,590,808 underlying)
Sofinnova Management X, L.L.C.
10% Owner
Holdings
Series A-2 Convertible Preferred Stock
→ Common Stock (1,590,808 underlying)
Katabi Maha
10% Owner
Holdings
Series A-2 Convertible Preferred Stock
→ Common Stock (1,590,808 underlying)
Footnotes (2)
- [F1]The Series A-2 Convertible Preferred Stock is convertible into Common Stock on a 7.4730-for-1 basis into the number of shares of Common Stock as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- [F2]The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001680200
Filing Metadata
- Form type
- 3
- Filed
- Jul 22, 8:00 PM ET
- Accepted
- Jul 23, 9:31 PM ET
- Size
- 14.6 KB